Rezdiffra (resmetirom) has potential interactions with other medications. These interactions could affect how well the drug works or cause harmful effects.

Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target underlying causes of MASH. The drug previously received accelerated approval from the U.S. Food and Drug ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Madrigal Pharmaceuticals Inc, a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced that the European Commission ...